Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Change in Accured Expenses (2020 - 2025)

GeneDx Holdings has reported Change in Accured Expenses over the past 6 years, most recently at $6.9 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $6.9 million for Q4 2025, up 154.38% from a year ago — trailing twelve months through Dec 2025 was $12.1 million (up 158.96% YoY), and the annual figure for FY2025 was $12.1 million, up 158.96%.
  • Change in Accured Expenses for Q4 2025 was $6.9 million at GeneDx Holdings, up from -$2.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for WGSWW hit a ceiling of $33.4 million in Q3 2022 and a floor of -$14.5 million in Q3 2023.
  • Median Change in Accured Expenses over the past 5 years was -$2.8 million (2025), compared with a mean of -$994650.0.
  • Peak annual rise in Change in Accured Expenses hit 65806.86% in 2021, while the deepest fall reached 1838.06% in 2021.
  • GeneDx Holdings' Change in Accured Expenses stood at -$1.7 million in 2021, then surged by 449.64% to $5.9 million in 2022, then crashed by 256.79% to -$9.3 million in 2023, then plummeted by 37.42% to -$12.7 million in 2024, then skyrocketed by 154.38% to $6.9 million in 2025.
  • The last three reported values for Change in Accured Expenses were $6.9 million (Q4 2025), -$2.0 million (Q3 2025), and -$3.6 million (Q2 2025) per Business Quant data.